[Federal Register Volume 69, Number 222 (Thursday, November 18, 2004)]
[Notices]
[Page 67597]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-25575]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of 
the Recombinant DNA Advisory Committee.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: Recombinant DNA Advisory Committee.
    Date: December 16-17, 2004.
    Time: 8:30 a.m. to 6 p.m.
    Agenda: Review of human gene transfer protocols for Development 
of effective immunotherapy for prostate cancer patients and a Phase 
I clinical trial of rAAV2.5-CMV-mini-dystrophin gene vector in 
Duchenne Muscular Dystrophy. The meeting includes the Data 
Management report and discussion of the draft Points to Consider 
from the September Safety Symposium. Please refer to the OBA-RAC web 
site for updates.
    Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 
20814.
    Contact Person: Stephen M. Rose, PhD, Executive Secretary, 
Office of Biotechnology Activities, National Institutes of Health, 
6705 Rockledge Drive, Room 750, Bethesda, MD 20892, 301-496-9838, 
301-496-9838, [email protected].
    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    Information is also available on the Institute's/Center's home 
page: http://www4.od.nih.gov/oba/, where an agenda and any 
additional information for the meeting will be posted when 
available.
    OMB's ``Mandatory Information Requirements for Federal 
Assistance Program Announcements'' (45 FR 39592, June 11, 1980) 
requires a statement concerning the official government programs 
contained in the Catalog of Federal Domestic Assistance. Normally 
NIH lists in its announcements the number and title of affected 
individual programs for the guidance of the public. Because the 
guidance in this notice covers virtually every NIH and Federal 
research program in which DNA recombinant molecule techniques could 
be used, it has been determined not to be cost effective or in the 
public interest to attempt to list these programs. Such a list would 
likely require several additional pages. In addition, NIH could not 
be certain that every Federal program would be included as many 
Federal agencies, as well as private organizations, both national 
and international, have elected to follow the NIH Guidelines. In 
lieu of the individual program listing, NIH invites readers to 
direct questions to the information address above about whether 
individual programs listed in the Catalog of Federal Domestic 
Assistance are affected.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.22, Clinical Research Loan 
Repayment Program for Individuals from Disadvantaged Backgrounds; 
93.232, Loan Repayment Program for Research Generally; 93.39, 
Academic Research Enhancement Award; 93.936, NIH Acquired 
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, 
Undergraduate Scholarship Program for Individuals from Disadvantaged 
Backgrounds, National Institutes of Health, HHS)


    Dated: November 10, 2004.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 04-25575 Filed 11-17-04; 8:45 am]
BILLING CODE 4140-01-M